Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06119256
PHASE1

Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT

Sponsor: Chinese PLA General Hospital

View on ClinicalTrials.gov

Summary

This is a multi-center, single arm, open-label, phase I study to determine the safety and effectiveness of EBV-TCR-T cell immunotherapy in treating EBV virus infection after allogenic HSCT.

Official title: Multicenter, Open Label, Single-arm Exploratory Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT

Key Details

Gender

All

Age Range

14 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2023-08-01

Completion Date

2028-12-31

Last Updated

2026-04-02

Healthy Volunteers

No

Interventions

BIOLOGICAL

EBV-TCR-T cells

The patients with EBV infection after HSCT will receive one to three infusions of donor-derived EBV-TCR-T cells, with the escalated dose ranging from 5×10\^5/kg to 1×10\^6/kg EBV-TCR-T cells per dose.

Locations (1)

Chinese PLA General Hospital

Beijing, Beijing Municipality, China